Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 4
Journal homepage
13
Views
18
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Overview: ACAT Inhibitors: A Potential New Approach to the Treatment of Hypercholesterolaemia and Atherosclerosis

Patrick M O'Brien Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105 USA
&
Drago R Sliskovic Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105 USA
Pages 507-526 | Published online: 02 Mar 2011

References to Primary Literature

  • The Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial Results. J. Am. Med. Assoc. 1984 251 251.
  • Frick MH, Elo H, Haapa K, Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N. Engl. J. Med. 1987 317 1237.
  • Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L Beneficial effects of colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J. Am. Med. Assoc. 1987 257 3233.
  • Grundy SM HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. N. Engl. J. Med. 1988 319 24.
  • Brown G, Albers JJ, Fisher LD, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apo B. N. Engl. J. Med. 1990 323 1289.
  • Heider JG, Agents which inhibit cholesterol esterification in the intestine and their potential value in the treatment of hyper-cholesterolaemia, Pharmacological Control of Hyperlipidemia Fears R. Prous Science Pub 1986 423.
  • Tavani DM, Nes WR, Bilheimer JT The sterol specificity of acyl CoA: Cholesterol acyl transferase from rat liver. J. Lipid. Res. 1982 23 774.
  • Spector AA, Mathur SN, Kaduce TL Role of acyl coenzyme A: Cholesterol O-acyltransferase in cholesterol metabolism. Prog. Lipid Res. 1979 18 31.
  • Goldstein JL, Brown MS The low-density lipoprotein pathway and its relation to atherosclerosis. Ann. Rev. Biochem. 1977 46 897.
  • Gavey KL, Noland BJ, Scallen TJ The participation of sterol carrier protein in the conversion of cholesterol to cholesterol ester by rat liver microsomes. J. Biol. Chem. 1981 256 2993.
  • Schmitz G, Beuck M, Structural and functional properties of acyl-CoA: Cholesterol acyltransferase (ACAT), Biotechnology of Dyslipoproteinemias: Applications in Diagnosis and Control Lenfant C Raven Press 1990 79.
  • Gavey KL, Trujillo DL, Scallen TJ Evidence for phosphorylation/dephosphorylation of rat liver acyl-CoA:cholesterol acyltransferase. Proc. Natl. Acad. Sci. 1983 80 2171.
  • Einarsson K, Benthin L, Ewerth S, Hellers G, Stahlberg D, Angelin B Studies on acyl-coenzyme A: Choleserol acyltransferase activity in human liver microsomes. J. Lipid. Res. 1989 30 739.
  • Mathur SN, Armstrong ML, Alber CA, Spector AA Hepatic acylcoenzyme A: Cholesterol acyltransferase activity during diet-induced hypercholesterolaemia in cynomolgus monkeys. J. Lipid Res. 1981 22 659.
  • Doolittle GM, Chang TY Solubilization, partial purification and reconstitution in phosphatidylcholine-cholesterol liposomes of acyl-CoA: Cholesterol acyltransferase. Biochemistry 1982 21 674.
  • Billheimer JT, Cromley DA, Kempner ES The functional size of acyl-coenzyme A(CoA): Cholesterol acyltransferase and acyl-CoA hydrolase as determined by radiation inactivation. J. Biol. Chem. 1990 265 8632.
  • Kinnunen PM, DeMichele A, Lange LG Chemical modification of acyl-CoA: Cholesterol O-acyl-transferase. 1. Identification of acyl-CoA: Cholesterol O-acyltransferase subtypes by differential diethyl pyrocar-bonate sensitivity. Biochemistry 1988 27 7344.
  • Kinnunen PM, Spilburg CA, Lange LG Chemical modification of acyl-CoA: Cholesterol O-acyltransferase. 2. Identification of a coenzyme A regulatory site by p-mercuribenzoate modification. Biochemistry 1988 27 7351.
  • Goldstein JL, Brown MS Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J. Lipid Res. 1984 25 1450.
  • Krause BR, Holmes A, Stanfield R, Pharmacologic profile of PD 132301–2, a novel inhibitor of acyl-CoA: Cholesterol O-acyltransferase (ACAT). In vivo evidence for altering the secretion of both intestinal and hepatic lipoproteins. FASEB J. 1991 5 A946.
  • Khan B, Wilcox HG, Heimberg M Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem. J. 1989 259 807.
  • Nervi F, Bronfman M, Allalon W, Depiereux E, Del Pozo R Regulation of biliary cholesterol secretion in the rat Role of hepatic cholesterol esterification. J. Clin. Invest. 1984 74 2226.
  • Smith JL, De Jersey J, Pillay SP, Hardie IR Hepatic acyl-CoA: Cholesterol O-acyltransferase. Development of a standard assay and determination in patients with cholesterol gallstones. Clin. Chim. Acta. 1986 158 271.
  • Swell L, Byron JE, Treadwell CR Cholesterol esterases IV. Cholesterol esterase of rat intestinal mucosa. J. Biol. Chem. 1950 186 543.
  • Bennett CS, Tercyak AM Reduced trans-mucosal transport in rats with inhibited mucosal acyl-CoA: Cholesterol O-acyltransferase and normal hepatic function. J. Lipid. Res. 1984 25 148.
  • Heider JG, Pickens CE, Kelly LA Role of acyl CoA: Cholesterol acyltransferase in cholesterol absorption and its inhibition by 57–118 in the rabbit. J. Lipid. Res. 1983 24 1127.
  • Brown MS, Goldstein JL Lipoprotein metabolism in the macrophage: Implications for cholesterol depositions in atherosclerosis. Anna. Rev. Biochem. 1983 52 223.
  • Bell FP, Arterial cholesterol esterification by acyl CoA cholesterol acyltransferase: Its possible significance in atherogenesis and its inhibition by drugs, Pharmacological Control of Hyperlipidemia Fears R. Prous Science Pub 1986 409.
  • Fukushima H, Aono S, Nakatini H Effect of N-(α-methylbenzyl)linoleamide on lipid levels of plasma and liver in cholesterol-fed rats. J. Nutr. 1968 96 15.
  • Fukushima H, Aono S, Nakatini H Cholesterol-lowering effects of amide derivatives of linoleic acid in chickens and mice. J. Pharm. Soc. Japan 1969 89 857.
  • Natori K, Okazaki Y, Nakajima T, Hirohashi T, Aono S Mechanism of the inhibition of cholesterol absorption by DL-Melinamide: Inhibition of cholesterol esterification. Japan J. Pharmacol. 1986 42 517.
  • Toki K, Nakatami H Search for a new hypolipidemic agent. Artery 1975 1 251.
  • Toki K, Fukumaru T, Nakatini H, Fukushima H The prevention of experimental atherosclerosis by a novel linoleic acid derivative. J. Atheroscler. Res. 1967 7 708.
  • Tse FL, Jaffe JM Disposition of silicon-containing amide, an inhibitor of acyl-CoA: Cholesterol acyltransferase in dog and rat. Biopharmaceutics & Drug Disposition 1987 8 437.
  • Hirohashi A, Nagata A, Miyawaki H, Nakatini H, Toki K Metabolism of linole-amides. I. Absorption, excretion and metabolism of N-(α-methylbenzyl)linoleamide in rat and man. Xenobiotica 1976 6 329.
  • Woolf TF, Bjorge SM, Black AE, Holmes A, Chang T Metabolism of the acyl-CoA: Cholesterol acyltransferase inhibitor 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecan-amide in rat and monkey. Drug Metab. & Disp. 1991 19 696.
  • Field FJ, Albright E, Mathur S Inhibition of acylcoenzyme A: Cholesterol acyltransferase by PD-128042: Effect on cholesterol metabolism and secretion in CaCo-2 cells. Lipids 1991 26 1.
  • Krause BR, Hoefle ML, Holmes A, Roth BD, Kieft KA, Uhlendorf PD, Stanfield RL, Sekerke CS, Bocan TMA, Newton RS, Lipid regulating activity of PD-128042, a novel inhibitor of acyl-CoA: Cholesterol acyl-transferase (ACAT). 10th International Symposium on Drugs Affecting Lipid Metabolism Houston, US 1989 Abs 422.
  • Roth BD, Blankley CJ, Hoefle ML, Holmes A, Roark WH, Trivedi BK, Essenburg AD, Kieft KA, Krause BR, Stanfield RL Inhibitors of acyl-CoA: Cholesterol acyl-transferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents. J. Med. Chem. in press.
  • Krause BR, Bousley R, Kieft K, Stanfield R, Effects of the ACAT inhibitor CI-976 on plasma cholesterol concentrations and distribution in hamsters fed zero and low-cholesterol diets. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A97.
  • Bocan TMA, Mueller Bak S, Uhlendorf PD, Newton RS, Krause BR Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for anti-atherosclerotic activity in iliac-femoral and thoracic aortic lesions. A Biochemical, morphological, and morphometric evaluation. Arterioscler. Thromb. 1991 11 1830.
  • Bell FP The effect of local anesthetics on arterial lipid metabolism. Atherosclerosis 1981 38 81.
  • Bolton GL., Blankley CJ, Padia JK, Roth BD, Trtvedi BK, Essenburg AD, Bousley RF, Hamelehle KL, Minton L, Stanfield RL, Krause BR, Synthesis and hypocholesterolemic activity of novel phosphorous-containing ACAT inhibitors. 202nd ACS Meeting New York, US 1991 MEDI 110.
  • Augelli-Szafran CE, Blankley CJ, Roth BD, Trtvedi BK, Bousley RF, Essenburg AD, Hamelehle KL, Minton L, Sekerke CS, Stanfield RL, Krause BR, Novel substituted β-ketoamide ACAT inhibitors: Chemistry and biological activity. 202nd ACS Meeting New York, US 1991 MEDI 108.
  • Ashton MJ, Bridge AW, Bush RC, Dron DI, Joannou PP, Riddell D, Roberts S, Stevenson GVW, Warne PJ, RP-64477: A potent inhibitor of acyl-CoA: Cholesterol O-acyl-transferase (ACAT). 9th International Symposium on Atherosclerosis Rosemont, US 1991 A92.
  • Largis EE, Wang CH, De Vries VG, Schaffer SA CL-277082: A novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J. Lipid Res. 1989 30 681.
  • Largis EE, Katocs AS, Wang CH, Schaffer SA, Effect of CL-277082 on cholesterol esterification in vitro and on cholesterol absorption in the rat. 7th International Symposium on Atherosclerosis Melbourne 1985 A63.
  • Harris WS, Dujovne CA, Von Bergmann K, Neal J, Akester J, Windsor S, Greene D, Look Z Effects of the ACAT inhibitor CL-277082 on cholesterol metabolism in humans. Clin. Pharmacol. Ther. 1990 48 189.
  • Gallo LL, Wadsworth JA, Vahouny GV Normal cholesterol absorption in rats deficient in intestinal acyl coenzyme A: Cholesterol acyltransferase activity. J. Lipid. Res. 1987 28 381.
  • Largis EE, Katoc AS, Trisubstituted ureas are potent inhibitors of ACAT and dietary cholesterol absorption. 10th International Symposium on Drugs Affecting Lipid Metabolism Houston, US 1989 A314.
  • Stoeber TL, Holmes A, Essenburg AD, Hamelehle KL, Shaw MK, Stanfield RL, Krause BR, Trtvedi BK, Chemistry and SAR studies of novel trisubstituted urea ACAT inhibitors. 201st ACS Meeting Atlanta, US 1991 MEDI 113.
  • Billheimer JT, Cromley DA, Higley CA, Wexler RR, Robinson CS, Gilles PJ, The diarylthio-imidazole, DuP-128, is a potent inhibitor of acyl-CoA: Cholesterol acyltransferase (ACAT). 9th International Symposium on Atherosclerosis Rosemont, US 1991 A94.
  • Gilles PJ, Robinson CS, Higley CA, Wexler RR, Billheimer JT, Inhibition of intestinal acyl-CoA: Cholesterol acyltransferase (ACAT) by DuP-128 in a cholesterol-fed hamster model of hypercholesterolemia. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A93.
  • Iizumi Y, Yanagita Y, Masuyama Y, Ohtsuka H, Kakuta H, Fujimuri N, Itoh N, Matsuda K, Ohata I, Lipid-lowering and anti-atherosclerotic activity of YM-17E, an inhibitor of acyl-CoA: Cholesterol acyltransferase (ACAT) in animal models. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A96.
  • Harnett KM, Walsh CT, Zhang L Effects of BAYo2752, a hypocholesterolemic agent, on intestinal taurocholate absorption and cholesterol esterification. J. Pharm. Exp. Ther. 1989 251 502.
  • Kusunuki J, Aragane K, Kase N, Ikawa H, Yamaura T, Saito Y, Hypolipidemic action of F-1394, a newly synthesized ACAT inhibitor. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A90.
  • Roark WH, Roth BD, Holmes A, Kieft K, Essenburg AD, Stanfield RL, Krause BR, Modification of oleic acid anilide ACAT inhibitors: Replacement of the amide bond. 198th ACS Meeting Miami, US 1989 MEDI 72.
  • Trivedi BK, Holmes A, Stoeber TL, Shaw MK, Essenburg AD, Stanfield RL, Krause BR, A series of substituted N-phenyl-N′-(1-phenylcycloalkyl) ureas as inhibitors of ACAT: Chemistry and SAR studies. 200th ACS Meeting Washington, US 1990 MEDI 122.
  • Arrowsmith RJ, Dann JG, Harris CJ, Honey AC, O'Connor K, A potent and novel inhibitor of human ACAT. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A99.
  • Balasubramanian S, Simons LA, Chang S Effects of Rol6–0521 on cholesterol metabolism in the rat. Atherosclerosis 1986 60 263.
  • Rucker W, Prop G, Huther A Anti-atherosclerotic and antihyperlipidemic effects of octimibate sodium in rabbits. Atherosclerosis 1988 69 155.
  • Weisweiler P, Gopfert E Lipid-lowering properties of the ACAT inhibitor octimibate in hypercholesterolemic subjects. Atheroscler. Thromb. 1991 11 1497.
  • Wexler RR, Higley CA, Maduskule TP, Pennev P, Billheimer JT, Gillies PJ, Acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors: Synthesis and SAR studies of a new series of trisubstituted imidazoles. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A98.
  • Ashton MJ, Bridge AW, Bush RC, Dron DI, Harris NV, Lythgoe DJ, Riddell D, Smith S, RP-70676: A potent systemically available inhibitor of acyl-CoA: Cholesterol O-acyltransferase (ACAT). 9th International Symposium on Atherosclerosis Rosemont, US 1991 A100.
  • De Vries VG, Moran DB, Allen GR, Riggi SJ Hypolipidemic benzoic acids. J. Med. Chem. 1976 19 946.
  • Hollander W, Pristy S, Nagraj S, Kirkpatrick B, Paddock J, Colombo M Comparative effects of cetaben (PHB) and dichloromethylene diphosphonate (C12MDP) on the development of atherosclerosis in cynomolgus monkey. Atherosclerosis 1978 31 307.
  • Albright JD, DeVries VG, Du MT, Largis EE, Minor TG, Reich MF, Shepherd RG Potential anti-atherosclerotic agents. Substituted benzoic and non-benzoic acid analogues of cetaben. J. Med. Chem. 1983 26 1393.
  • Zilversmit DB A single blood sample dual isotope method for the measurement of cholesterol absorption in rats. Pro. Soc. Exp. Biol. Med. 1972 140 862.
  • Larsen SD, Spilman CH, Bell FP, Dinh DM, Martinburough E, Wilson GJ Synthesis and hypocholesterolemic activity of 6,7-dihydro-4H-pyrazolo[1,5-a]-pyrrolo[3,4-d] pyrimidine-5,8-di-ones, novel inhibitors of acyl-CoA: Cholesterol O-acyltransferase. J. Med. Chem. 1991 34 1721.
  • Gammill RB, Bell FP, Bell LT, Bisaha SN, Wilson GJ Anti-atherosclerotic agents. Structurally novel bivalent inhibitors of acyl-CoA: Cholesterol O-acyltransferase with systemic activity. J. Med. Chem. 1990 33 2685.
  • Bell FP, Gammill RB, Vidmar TJ, Systemic ACAT inhibition with triglyceride-lowering and HDL-elevating activities of structurally novel bivalent ligands with oral absorption: The bisaminofurochromones. 9th International Symposium on Atherosclerosis Rosemont, US 1991 A95.
  • Heffron F, Middleton B, White D Inhibition of acyl-CoA: Choleserol acyltransferase by trimethylcyclohexanyl-mandelate (cyclandelate). Biochem. Pharmacol. 1990 39 575.
  • Middleton B, Middleton A, White DA, Bell GD Dietary cyclandelate decreased pre-established atherosclerosis in the rabbit. Atherosclerosis 1984 171 171.
  • Tomada H, Nishida H, Masuma R, Cao J, Okuda S, Omura S Purpactins, new inhibitors of acyl-CoA: Cholesterol acyltransferase produced by Penicillium purpurogenom. J. Antiobiot. 1991 44 136.
  • Tabas I, Chen L, Clader JW, McPhail AT, Burnett DA, Bartner P, Das PR, Pramanik BN, Puar MS, Feinmark SJ, Zipkin RE, Boykow G, Vita G, Tall A Rabbit and human liver contain a novel pentacyclic triterpine ester with acyl-CoA: Cholesterol acyltransferase activity. J. Biol. Chem. 1990 265 8042.
  • Sliskovic DR, White AD Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci. 1990 12 194.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.